
|Articles|January 1, 2005
A color atlas of cervical lesions
A color atlas of cervical lesions
Advertisement
Advertisement
Related Content
Advertisement




88 Imlunestrant With or Without Abemaciclib in Advanced Breast Cancer (ABC): A Subgroup Analysis in CDK4/6 Inhibitor (CDK4/6i)-Pretreated Patients From EMBER-3
ByCristina Saura,Lisa A. Carey, MD,Giuseppe Curigliano,Nadia Harbeck, MD, PhD,Joyce O’Shaughnessy, MD,François-Clément Bidard,Monica Lis Casalnuovo,Sung-Bae Kim,Eriko Tokunaga,Norikazu Masuda,Junichiro Watanabe,Xiaojia Wang,Quchang Ouyang,Hee Kyung Ahn,Christoph Cramer von Laue,Shanshan Cao,Holly Knoderer,Komal L. Jhaveri,Philippe Aftimos

89 Imlunestrant With or Without Abemaciclib as First- and Second-Line Therapy in Advanced Breast Cancer (ABC): A Subgroup Analysis From the EMBER-3 Trial
ByPatrick Neven, MD, PhD,Andre Mattar,Antonio Llombart-Cussac,Giuseppe Curigliano,Nadia Harbeck, MD, PhD,Joyce O’Shaughnessy, MD,François-Clément Bidard,Monica Lis Casalnuovo,Sung-Bae Kim,Eriko Tokunaga,Cristina Saura,Lisa A. Carey, MD,Kamnesh R. Pradhan,Shanshan Cao,Monique Coersmeyer,Anna Emde,Francisco Sapunar,Komal L. Jhaveri,Philippe Aftimos
Advertisement
Advertisement
Trending on CancerNetwork
1
Sac-TMT Combo Improves PFS vs Pembrolizumab in NSCLC
2
ASCO 2026: Key Genitourinary Oncology Trials to Watch For
3
Pembrolizumab Plus Chemotherapy Shows Sustained Survival in Advanced EC
4
Elranatamab Shows Strong Efficacy Signal in Smoldering Multiple Myeloma
5





























































